OrbiMed

A global healthcare investment firm investing across various stages and sectors within the healthcare industry.

Venture Capital Active New York City, United States Est. 1989
Visit website ↗ LinkedIn
Last updated 2026-07-20
Portfolio
11
in our dataset
Rounds participated
17
Rounds led
0
Rounds' value
$275.6M
total disclosed, rounds participated
Stages
A Round, Seed, C Round, B Round, D Round, F Round, E Round, G Round

About

OrbiMed is a leading global investment firm dedicated exclusively to the healthcare sector. They invest across the entire spectrum of pharmaceutical, biotechnology, and medical device companies on a worldwide basis, from seed-stage venture capital to large publicly-traded corporations. OrbiMed utilizes a range of investment vehicles including private equity funds, public equity funds, and royalty/credit funds.

Portfolio · 11

Ramino-Bio
Oral drug for treating cardio-metabolic disease and rare MSUD
1 round Latest: 2018-09
SmartZyme Biopharma
Improving Enzymes for Glucose Monitoring
2 rounds $4.0M committed Latest: 2018-03
Atox Bio
Immunomodulators for Treatment of Infectious and Inflammatory Diseases
2 rounds $53.0M committed Latest: 2017-12
Mitoconix Bio
Therapeutics for Neurodegenerative Diseases
1 round $20.0M committed Latest: 2017-06
Tisbury Pharmaceuticals
Open-angle Glaucoma Treatment
1 round $32.0M committed Latest: 2017-06
LogicBio Therapeutics
Gene Therapy for Genetic and Infectious Diseases
2 rounds $49.0M committed Latest: 2017-06
Pi Therapeutics
Inhibitors for Cancer Treatment
1 round Latest: 2017-01
Nutrinia
Neonatal Gastrointestinal Treatment
2 rounds $42.0M committed Latest: 2016-08
Ornim Medical
Noninvasive Cerebral Blood Flow Monitoring
3 rounds $50.0M committed Latest: 2016-08
Xylo Technologies
Minimally Invasive Endosurgical and Imaging Tools
1 round $11.1M committed Latest: 2014-06
Treato
Analysis of Prescription Drug Reviews
1 round $14.5M committed Latest: 2013-04

Investment activity

9 portfolio exits on record.

Portfolio by sector

Health Tech & Life Sciences38
Undisclosed2
Aerospace, Defense & HLS1

Funds · 8

  • OrbiMed Royalty & Credit Opportunities IV — $1.43B Oct 2023
  • OrbiMed Private Investments IX — $1.43B Oct 2023
  • OrbiMed Asia Partners V — $1.43B Oct 2023
  • Fund — $800M Mar 2021
  • Fund — $1.2B Mar 2021
  • Fund — $1.5B Mar 2021
  • 2 — $307M Jan 2016
  • 1 — $122M Jan 2010

Q&A

What is OrbiMed's primary investment focus?
OrbiMed is a dedicated healthcare investment firm, focusing on the global healthcare industry, including biopharmaceuticals, medical devices, diagnostics, and healthcare services.
What was OrbiMed's most recent exit?
OrbiMed had an exit in October 2024 with the acquisition of ImmPACT Bio by Lyell Immunopharma.
What is OrbiMed's most recent fund close?
In October 2023, OrbiMed closed three funds, OrbiMed Royalty & Credit Opportunities IV, OrbiMed Private Investments IX, and OrbiMed Asia Partners V, each raising $1.43 billion.
Which portfolio company did OrbiMed exit via a reverse merger in March 2021?
OrbiMed exited Chemomab Therapeutics in March 2021 through a reverse merger with Anchiano Therapeutics, which was listed on NASDAQ.
Can you name a notable public exit for OrbiMed in 2019?
In November 2019, OrbiMed had a public exit with 89bio through a POEvent, raising $85 million on NASDAQ.
What is an example of OrbiMed's recent portfolio company investments?
OrbiMed has invested in companies such as Upstream Bio, which raised $400 million in a Series B round, and Averna Therapeutics, which raised $82 million in a Series A round.
What is the typical investment stage for OrbiMed?
OrbiMed invests across various stages, including Seed, A Round, B Round, C Round, D Round, E Round, F Round, and G Round.
Where is OrbiMed headquartered and where does it have other offices?
OrbiMed is headquartered in New York, with additional offices in San Francisco, Mumbai, Hong Kong, and Shanghai.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)